Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q8CGN4

Entry ID Method Resolution Chain Position Source
AF-Q8CGN4-F1 Predicted AlphaFoldDB

115 variants for Q8CGN4

Variant ID(s) Position Change Description Diseaes Association Provenance
rs3389547830 3 S>F No EVA
rs3389500841 15 M>I No EVA
rs3389547947 17 S>G No EVA
rs3389460979 46 R>G No EVA
rs220410095 50 P>S No EVA
rs261514536 52 S>N No EVA
rs231322929 54 S>N No EVA
rs3389508950 55 V>M No EVA
rs3389554027 58 T>I No EVA
rs3389547944 92 G>C No EVA
rs3389553018 92 G>D No EVA
rs3389552999 96 L>V No EVA
rs3389565292 106 P>L No EVA
rs3389508790 144 G>D No EVA
rs3413000873 182 N>K No EVA
rs3389531502 190 P>L No EVA
rs3389562663 232 P>S No EVA
rs3409414637 234 Y>* No EVA
rs3389460927 234 Y>* No EVA
rs3389547990 257 I>T No EVA
rs3410117899 289 W>R No EVA
rs3409861510 295 P>R No EVA
rs3407543732 295 P>S No EVA
rs3409646313 298 P>L No EVA
rs3409743779 299 V>L No EVA
rs3409743768 300 D>G No EVA
rs3409698974 302 H>Q No EVA
rs3409199716 303 S>G No EVA
rs3409646251 304 Y>* No EVA
rs3409614707 306 H>P No EVA
rs232479516 350 A>T No EVA
rs3389568034 353 T>I No EVA
rs3389519344 402 C>Y No EVA
rs3389460995 425 P>A No EVA
rs3389565320 464 T>S No EVA
rs3389519408 474 G>D No EVA
rs3389562697 478 S>P No EVA
rs3389553016 478 S>Y No EVA
rs3389546941 511 V>S No EVA
rs3389565330 512 P>S No EVA
rs3389562683 514 P>S No EVA
rs3389508980 515 S>I No EVA
rs3389548006 542 S>F No EVA
rs3408510418 553 V>L No EVA
rs228938633 554 V>I No EVA
rs3408431652 564 S>WAS* No EVA
rs3409614743 598 Q>* No EVA
rs3389557610 651 A>E No EVA
rs3409861547 726 V>G No EVA
rs3409698981 733 H>P No EVA
rs3408431591 734 T>R No EVA
rs3407543757 748 S>Y No EVA
rs3389460945 754 A>S No EVA
rs3409511933 797 T>S No EVA
rs221151863 818 T>A No EVA
rs249994696 842 S>T No EVA
rs232350030 847 I>M No EVA
rs215571669 850 R>C No EVA
rs246303562 854 I>T No EVA
rs3409646241 942 P>L No EVA
rs229466741 943 A>S No EVA
rs3408510425 944 Y>H No EVA
rs3409698842 1037 E>A No EVA
rs3408510358 1043 T>N No EVA
rs3409743823 1050 K>T No EVA
rs1132683426 1078 D>G No EVA
rs259109601 1082 S>T No EVA
rs3408510349 1089 T>P No EVA
rs3389553009 1104 L>H No EVA
rs252604352 1121 S>N No EVA
rs3389554038 1133 T>A No EVA
rs241414395 1135 R>P No EVA
rs3389553359 1178 M>V No EVA
rs3389553025 1180 N>Y No EVA
rs3389546995 1200 C>* No EVA
rs3389553991 1205 G>R No EVA
rs3389460985 1220 R>W No EVA
rs3389554031 1232 P>S No EVA
rs3409861464 1244 V>D No EVA
rs3408877001 1247 E>G No EVA
rs3389531561 1254 N>K No EVA
rs3389553328 1276 E>* No EVA
rs220099592 1310 T>I No EVA
rs3409743806 1338 T>A No EVA
rs262766609 1339 G>E No EVA
rs262766609 1339 G>V No EVA
rs218453078 1341 D>E No EVA
rs239011438 1341 D>V No EVA
rs254929587 1342 E>G No EVA
rs3408430684 1349 P>L No EVA
rs3389508948 1357 I>N No EVA
rs3389508948 1357 I>S No EVA
rs3389553361 1387 Y>C No EVA
rs3389568035 1388 V>L No EVA
rs3389460955 1444 P>H No EVA
rs3408510298 1453 M>L No EVA
rs3389508918 1461 I>N No EVA
rs3389460907 1487 L>M No EVA
rs3389565297 1494 V>I No EVA
rs3412971211 1496 H>N No EVA
rs3389531580 1503 C>Y No EVA
rs3389531523 1531 A>V No EVA
rs3409861504 1541 A>V No EVA
rs3389554034 1580 E>A No EVA
rs3389460996 1598 T>I No EVA
rs250192487 1634 E>D No EVA
rs3389553305 1638 S>I No EVA
rs3389557630 1643 F>L No EVA
rs3389553031 1662 Q>R No EVA
rs3389519361 1687 N>I No EVA
rs3389562736 1689 P>H No EVA
rs3389519339 1704 Q>H No EVA
rs3409504025 1731 V>E No EVA
rs3389546355 1737 L>F No EVA
rs3389547975 1738 Q>K No EVA

No associated diseases with Q8CGN4

2 regional properties for Q8CGN4

Type Name Position InterPro Accession
domain W2 domain 248 - 415 IPR003307
domain BZW1/2, W2 domain 218 - 408 IPR043510

Functions

Description
EC Number
Subcellular Localization
  • Nucleus
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

3 GO annotations of cellular component

Name Definition
BCOR complex A protein-containing complex that monoubiquitinates histone H2A on K119, thus it facilitates the maintenance of the transcriptionally repressive state of some genes, such as BCL6. It consists of the corepressor BCOR or BCORL1, a Polycomb group (PcG) and a SCF ubiquitin ligase subcomplexes. In mammals, the core subunits of the complex include the PcG and PcG-associated proteins NSPC1, RING1, RNF2, and RYBP and the components of the SCF ubiquitin ligase, SKP1, and FBXL10.
nucleoplasm That part of the nuclear content other than the chromosomes or the nucleolus.
nucleus A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.

7 GO annotations of molecular function

Name Definition
DNA-binding transcription factor binding Binding to a DNA-binding transcription factor, a protein that interacts with a specific DNA sequence (sometimes referred to as a motif) within the regulatory region of a gene to modulate transcription.
heat shock protein binding Binding to a heat shock protein, a protein synthesized or activated in response to heat shock.
histone deacetylase binding Binding to histone deacetylase.
RNA polymerase II transcription regulatory region sequence-specific DNA binding Binding to a specific sequence of DNA that is part of a regulatory region that controls the transcription of a gene or cistron by RNA polymerase II.
transcription cis-regulatory region binding Binding to a specific sequence of DNA that is part of a regulatory region that controls transcription of that section of the DNA. The transcribed region might be described as a gene, cistron, or operon.
transcription corepressor activity A transcription coregulator activity that represses or decreases the transcription of specific gene sets via binding to a DNA-bound DNA-binding transcription factor, either on its own or as part of a complex. Corepressors often act by altering chromatin structure and modifications. For example, one class of transcription corepressors modifies chromatin structure through covalent modification of histones. A second class remodels the conformation of chromatin in an ATP-dependent fashion. A third class modulates interactions of DNA-bound DNA-binding transcription factors with other transcription coregulators.
ubiquitin-protein transferase activity Catalysis of the transfer of ubiquitin from one protein to another via the reaction X-Ub + Y --> Y-Ub + X, where both X-Ub and Y-Ub are covalent linkages.

12 GO annotations of biological process

Name Definition
blastocyst hatching The hatching of the cellular blastocyst from the zona pellucida.
chromatin organization The assembly or remodeling of chromatin composed of DNA complexed with histones, other associated proteins, and sometimes RNA.
heart development The process whose specific outcome is the progression of the heart over time, from its formation to the mature structure. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood.
histone H2A monoubiquitination The modification of histone H2A by addition of a single ubiquitin group.
negative regulation of bone mineralization Any process that stops, prevents, or reduces the frequency, rate or extent of bone mineralization.
negative regulation of histone H3-K36 methylation Any process that stops, prevents, or reduces the frequency, rate or extent of the covalent addition of a methyl group to the lysine at position 36 of histone H3.
negative regulation of histone H3-K4 methylation Any process that stops, prevents, or reduces the frequency, rate or extent of the covalent addition of a methyl group to the lysine at position 4 of histone H3.
negative regulation of tooth mineralization Any process that stops, prevents, or reduces the frequency, rate or extent of tooth mineralization, the deposition of calcium salts in tooth structures.
negative regulation of transcription by RNA polymerase II Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase II.
odontogenesis The process whose specific outcome is the progression of a tooth or teeth over time, from formation to the mature structure(s). A tooth is any hard bony, calcareous, or chitinous organ found in the mouth or pharynx of an animal and used in procuring or masticating food.
roof of mouth development The biological process whose specific outcome is the progression of the roof of the mouth from an initial condition to its mature state. This process begins with the formation of the structure and ends with the mature structure. The roof of the mouth is the partition that separates the nasal and oral cavities.
specification of axis polarity The pattern specification process in which the polarity of a body or organ axis is established and maintained.

No homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
No homologous proteins
10 20 30 40 50 60
MLSATPLYGN VHSWMNSERV RMCGTSEDRK IPVNDGDASK ARLELREETP LSHSVVDTSG
70 80 90 100 110 120
AHRIDGLAAL SMDRTGLIRE GLRVPGNIVY SGLCGLGSEK GREATPSSLS GLGFSSERNP
130 140 150 160 170 180
EMQFKPNTPE TVEASAVSGK PPNGFSAIYK TPPGIQKSAV ATAESLGLDR PASDKQSPLN
190 200 210 220 230 240
INGASYLRLP WVNPYMEGAT PAIYPFLDSP NKYSLNMYKA LLPQQSYGLA QPLYSPVCTS
250 260 270 280 290 300
GERFLYLPPP HYVNPHIPSS LASPMRLSTP SASAAIPPLV HCSDKSLPWK MGVNPGNPVD
310 320 330 340 350 360
SHSYPHIQNS KQPRVTSAKA VNSGLPGDTA LLLPPSPRPS ARVHLPTQPA AETYSEFHKH
370 380 390 400 410 420
YPRISTSPSV TLTKPYMTAN SEFSTSRLSN GKYPKALDGG DCAQSMPGHT RKTTVQDRKD
430 440 450 460 470 480
GGSPPLLEKQ TVTKDVTDKP LDLSSKVVDA DASKGDHMKK MAPTVLVHSR AASGLVLSGS
490 500 510 520 530 540
EIPKETLSPP GNGCSIYRSE IISTAPSSWV VPGPSPNEEN NGKSLSLKNK ALDWAIPQQR
550 560 570 580 590 600
SSSCPRMGGT DAVVTNVSGS VSSSGRPASA SPAPNANANA DGTKTSRSSV DTTPSVIQHV
610 620 630 640 650 660
GQPSSTPAKH GGSTSSKGAK ANPEPSFKAS ENGLPPTSIF LSPNEAFRSP AIPYPRSYLP
670 680 690 700 710 720
YAAPEGIALS PLSLHGKGPV YPHPVLLPNG SLFPGHLAPK PGLPYGLHTS RPEFVTYQDA
730 740 750 760 770 780
LGLGMVHPML IPHTPIEITK EEKPERRSRS HERARYEDPT LRSRFSEMLE ASSTKLHPEV
790 800 810 820 830 840
PTDKNLKPNS SWNQGKTGVK SDKLVYVDLL REEADTKTDA GAPKAGLVAE NVGQDTEATK
850 860 870 880 890 900
PSADPVIQQR REFISLREEL GRITDFHESF TFKQASSQPV FSLGKDSGAA GTNKENLGVQ
910 920 930 940 950 960
VATPFLETAL GSEGPAVTFG KTQEDPKPFC VGGAPPNMDV TPAYTKEGTD EAESNDGKVL
970 980 990 1000 1010 1020
KPKPSKLAKR IANSAGYVGD RFKCVTTELY ADSSQLSREQ RALQMEGLQE DSILCLPAAY
1030 1040 1050 1060 1070 1080
CERAMMRFSE LEMKEREGSH PATKDSEVCK FSPADWERLK GNQEKKPKSV TLEEAIADQN
1090 1100 1110 1120 1130 1140
DSERCEYSTG NKHDLFEAPE DKDLPVEKYF LERPPVSEPP SDQGVVDTPH SPTLRLDRKR
1150 1160 1170 1180 1190 1200
KLSGDSTHTE TAVEELAEDP LKAKRRRISK DDWPEREMTN SSSNHLEDPH CNELTNLKVC
1210 1220 1230 1240 1250 1260
IELTGLHPKK QRHLLHLRER WEQQVSAAES KPGRQSRKEV AQAVQPEVTS QGTNITEEKP
1270 1280 1290 1300 1310 1320
GRKKAEAKGN RGWSEESLKS CDNEQGLPVL SGSPPMKSLS STNASGKKQT QPSCTPASRL
1330 1340 1350 1360 1370 1380
PAKQQKIKES QKTDVLCTGE DEDCQAASPL QKYTDNIEKP SGKRLCKTKH LIPQESRRSL
1390 1400 1410 1420 1430 1440
QITGDYYVEN TDTKMTVRRF RKRPEPSSDY DLSPPAKQEP KPFDRLQQLL PATQATQLPR
1450 1460 1470 1480 1490 1500
SNSPQETTQS RPMPPEARRL IVNKNAGETL LQRAARLGYE EVVLYCLENK VCDVNHRDNA
1510 1520 1530 1540 1550 1560
GYCALHEACA RGWLNIVRHL LEYGADVNCS AQDGTRPLHD AVENDHLEIV RLLLSYGADP
1570 1580 1590 1600 1610 1620
TLATYSGRTI MKMTHSELME KFLTDYLNDL QGRSEDDTSG AWEFYGSSVC EPDDESGYDV
1630 1640 1650 1660 1670 1680
LANPPGPEDP DEEEDTYSDL FEFEFAESSL LPCYNIQVSV AQGPRNWLLL SDVLKKLKMS
1690 1700 1710 1720 1730 1740
SRIFRSNFPN LEIVTIAEAE FYRQVSTSLL FSCPKDLEAF NPESKELLDL VEFTNELQTL
1750
LGSSVEWLHP SDTGHENYW